Evotech and Variant Bio partner to develop fibrosis treatment
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Commercial terms include research funding and milestones and/or royalty payments to Evotec based on the success of the program
Breakthrough Therapy designation for pain associated with DPN granted by FDA
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development
This facility manufactures APIs & formulations of oncology and non-oncology products.
The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations
Subscribe To Our Newsletter & Stay Updated